 |
Broadcast of "Contemporary Issues in Transplantation: Delayed Graft Function --
Clinical Implications and Case Management", a Satellite Symposium presented during the 33rd Annual
Scientific Meeting of the American Society of Nephrology, October 12, 2000 in Toronto, Ontario, Canada
This
program was provided by the Institute for Continuing Healthcare Education (ICHE). This was an approved
ASN satellite symposium. It was not part of the official 33rd Annual Meeting as planned by the ASN Program Committee.
To
access these talks at no charge
you need to first REGISTER WITH
HDCN at this link.
Program Overview
Delayed graft function (DGF) is the most common complication of
the immediate postoperative period in renal transplantation and
affects up to 50% of the cadaveric renal transplants in the United
States. Although the incidence and definition of DGF vary among
transplant centers, the consequences are uniform: prolonged hospital
stay, additional invasive procedures, and additional cost to the
patient and health-care system. This symposium will address the
incidence, clinical implications, and pathophysiology of DGF as
well as its pharmacoeconomic impact. In addition, a clinical review
of methods for prevention and treatment of DGF will be discussed.
The symposium is designed to include both the surgical and the
nephrology views on DGF and will conclude with a panel discussion
by the faculty.
Program Objectives
At the conclusion of this activity, participants should be able
to do the following:
- Describe
the incidence and clinical implications of delayed graft function
in renal transplantation.
- Summarize
the impact of delayed graft function in renal transplantation
on graft survival and on additional costs to the patient and
health-care system.
- Discuss
in detail the pathophysiology of delayed graft function in renal
transplantation.
- Discuss
current medical efforts to prevent and treat delayed graft function
in renal transplantation from the perspective of both the surgeon
and nephrologist.
Target
Audience
This program has been designed to meet the educational needs of
renal transplant surgeons and nephrologists with an interest in
transplant-related topics.
Accreditation
Contemporary Issues in Transplantation-Delayed Graft Function: Clinical Implications and Case Management was
developed by the Institute for Continuing Healthcare Education. The Institute of Continuing Healthcare Education is
accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education
for physicians.
Program participants at the symposium received up to 3 hours of Category 1 CME credit toward the AMA Physician's
Recognition Award. The Institute of Healthcare Education has approved this web broadcast of the symposium for
information only. The web broadcast is not approved for continuing education credit.
Commercial support
This activity was supported by an educational grant from SangStat. The Institute for Continuing Healthcare Education
recognizes and adheres to the ACCME Standards for Commercial Support of Continuing Medical Education.
|
Bloom
|
Brayman
|
Delmonico
|
Matas
|
Roy D. Bloom,
MD, Cochair. Assistant Professor of Medicine, Comedical
Director, Kidney/Pancreas Transplant Program, University of Pennsylvania,
Philadelphia, PA. (more)
Kenneth L. Brayman, MD, PhD, Cochair. Associate Professor of Surgery, University of
Pennsylvania, Philadelphia, PA. (more)
Francis L. Delmonico, MD. Professor of Surgery, Harvard
Medical School, Director of Renal Transplantation, Massachusetts
General Hospital, Medical Director, New England Organ Bank, Boston,
MA. (more)
Arthur J. Matas, MD. Professor of Surgery, Director of Renal
Transplantation, Fairview University Medical Center, Minneapolis,
MN. (more) |
|
Dr. Bloom
has received honoraria related to the development of educational
materials from SangStat. He has also received
honoraria related to speakers' bureau activities from SangStat.
Dr. Bloom has indicated that he will include the discussion of anti-thymocyte globulin (rabbit) for intra-operative
administration to prevent delayed graft function. Anti-thymocyte globulin (rabbit) has not been approved by the FDA for
this use in the United States. Dr. Bloom has indicated that he will not include the discussion of products that have
not been approved by the FDA for any use.
Dr. Brayman has received honoraria related to speakers'
bureau activities from SangStat. Wyeth-Ayerst
Laboratories, and Novartis Pharmaceuticals Corporation. He has
also received grant support related to research activities from
Novartis Pharmaceuticals Corporation, Wyeth-Ayerst Laboratories,
and Fujisawa Pharmaceutical Co.
Dr. Brayman has indicated that he will include the discussion of anti-thymocyte globulin (rabbit) for intra-operative
administration to prevent delayed graft function. Anti-thymocyte globulin (rabbit) has not been approved by the FDA for
this use in the United States. Dr. Brayman has indicated that he will not include the discussion of products that have
not been approved by the FDA for any use.
Dr. Delmonico has received honoraria related to formal
advisory activities from Genzyme Data Safety Monitoring Board.Dr.
Matas has received honoraria related to formal advisory activities
from Novartis Pharmaceuticals Corporation. He has also received
honoraria related to the development of educational materials
from SangStat.
Dr. Delmonico has indicated that his presentation will not include the discussion of unlabeled uses of commercial
products or products that have not yet been approved by the FDA for use in the United States for any purpose.
Dr. Matas has received grant support related to research
activities from Roche Pharmaceuticals, Novartis Pharmaceuticals
Corporation, Fujisawa Pharmaceutical Co., Wyeth-Ayerst Laboratories,
and SangStat.
Dr. Matas has indicated that his presentation will not include the discussion of unlabeled uses of commercial products
or products that have not yet been approved by the FDA for use in the United States for any purpose.
|
|
|
|
This
was not part of the official 33rd Annual Meeting as planned
by the ASN Program Committee. Supported by an unrestricted
educational grant from SangStat.
The opinions expressed in this publication are those of the participating faculty and not those of the Institute for
Continuing Healthcare Education, SangStat, or any manufacturers of products mentioned herein.
This educational activity may include the discussion of products for indications not approved by the FDA. Disclosures
of off-label discussions are found in the faculty section.
Participants are encouraged to consult the package inserts for all products for updated information and changes
regarding indications, dosages, and contraindications. This recommendation is particularly important with new or
infrequently used products.
Copyright © 2001, Institute for Continuing Healthcare Education (the Institute),
a division of CoMed Communications, Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means,
electronic or mechanical, without first obtaining written permission from the Institute.
|
|
|
|
